This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Cave H, van der Werff ten Bosch J, Suciu S, Guidal C, Waterkeyn C, Otten J, Bakkus M, Thielemans K, Grandchamp B, Vilmer E . Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer – Childhood Leukemia Cooperative Group New Engl J Med 1998 339: 591–598
van Dongen JJ, Seriu T, Panzer-Grumayer ER, Biondi A, Pongers-Willemse MJ, Corral L, Stolz F, Schrappe M, Masera G, Kamps WA, Gadner H, van Wering ER, Ludwig WD, Basso G, de Bruijn MA, Cazzaniga G, Hettinger K, van der Does-van den Berg A, Hop WC, Riehm H, Bartram CR . Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood Lancet 1998 352: 1731–1738
Brisco MJ, Condon J, Hughes E, Neoh SH, Sykes PJ, Seshadri R, Toogood I, Waters K, Tauro G, Ekert H . Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction Lancet 1994 343: 196–200
Pongers-Willemse MJ, Seriu T, Stolz F, d'Aniello E, Gameiro P, Pisa P, Gonzalez M, Bartram CR, Panzer-Grumayer ER, Biondi A, San Miguel JF, van Dongen JJ . Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: report of the BIOMED-1 CONCERTED ACTION: investigation of minimal residual disease in acute leukemia Leukemia 1999 13: 110–118
Deane M, Norton JD . Immunoglobulin heavy chain variable region family usage is independent of tumor cell phenotype in human B linkeage leukemias Eur J Immunol 1999 20: 2209–2217
Janka-Schaub GE, Harms DO, den Boer ML, Veerman AJ, Pieters R . In vitro drug resistance as independent prognostic factor in the study COALL-05-92. Treatment of childhood acute lymphoblastic leukemia; two-tiered classification of treatments based on accepted risk criteria and drug sensitivity profiles in study COALL-06-97 Klin Padiat 1999 211: 233–238
Gruhn B, Hongeng S, Yi H, Hancock ML, Rubnitz JE, Neale GAM, Kitchingham GR . Minimal residual disease after intensive induction therapy in childhood acute lymphoblastic leukemia predicts outcome Leukemia 1998 12: 675–681
zur Stadt U, Harms DO, Schlüter S, Schrappe M, Goebel U, Spaar H, Janka G, Kabisch H . Outcome prediction by means of MRD at the end of induction therapy in childhood acute lymphoblastic leukemia strongly depends on the therapeutic regimen: a report of the German COALL study Blood 1999 94: 284a (Abstr.)
Acknowledgements
Part of the data was already presented at the 41st annual meeting of the American Society of Hematology.8 This work was supported by the Fördergemeinschaft Kinderkrebszentrum Hamburg. The authors gratefully acknowledge the participants of the German COALL study: Dr Pongratz (Augsburg); Dr Otte, Dr Jorch (Bielefeld-Bethel); Dr Siegert, Dr Lauterbach (Dresden); PD Dr Beck (Greifswald); Dr Knust (Iserlohn); Dr von Klinggraef (Kiel); Dr Thomas, Dr Völpel (Krefeld); Prof Dr Gutjahr (Mainz); Dr Müller (Mönchengladbach); Dr Klose (München-Harlaching); Prof Dr Drescher (Oldenburg); Dr Helmig (Regensburg); Dr Weber (Wiesbaden); Dr Dohrn (Wuppertal).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
zur Stadt, U., Harms, D., Schlüter, S. et al. MRD at the end of induction therapy in childhood acute lymphoblastic leukemia: outcome prediction strongly depends on the therapeutic regimen. Leukemia 15, 283–285 (2001). https://doi.org/10.1038/sj.leu.2402019
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2402019
This article is cited by
-
Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18–20 September 2008
Leukemia (2010)
-
Treatment of pediatric acute lymphoblastic leukemia: Progress achieved and challenges remaining
Current Hematologic Malignancy Reports (2007)
-
Minimal residual disease detection in childhood precursor–B-cell acute lymphoblastic leukemia: relation to other risk factors. A Children's Oncology Group study
Leukemia (2003)
-
Prognostic factors in childhood acute lymphoblastic leukemia
The Indian Journal of Pediatrics (2003)
-
Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936
Leukemia (2003)